Top-Star Rita Ora bringt 2000 Besucher beim Channel Aid live in Concert in der Elbphilharmonie Hamburg zum Tanzen
Hamburg (ots) - In sechs Tagen feiert die Elbphilharmonie Hamburg ihren 1. Geburtstag. Aber ein Konzertabend ...
Köln (ots) - - Beim kleinsten europäischen SUV-Modell von Ford besteht die Abdeckung des Laderaumbodens ...
Mainz (ots) - In der ersten Ausgabe 2018 blickt "ZDFzoom" auf Themen vergangener investigativer Dokumentationen ...
Hamburg and Calgary, Canada, June 22, 2010 (ots/PRNewswire) - Resverlogix Corp. ("Resverlogix" or the "Company") announced today that key scientific data was communicated in an oral presentation highlighting the novel features of the Company's lead drug RVX-208 at the European Atherosclerosis Society Congress (EAS) conference being held in Hamburg, Germany. The presentation titled "RVX-208 given orally raises plasma ApoA-I and HDL in human clinical trials," was presented by Dr. Norman Wong, MD, Chief Scientific Officer of Resverlogix.
"The data presented in Germany today further highlights that patients with low HDL/Apo-Al benefit most. For those patients in the highest risk category, subjects with low baseline HDL/Apo-Al, our data demonstrated that RVX-208 increased plasma levels of Apo-Al in the order of 13.25% compared to placebo. This data, combined with similar low baseline HDL/Apo A-l data analysis of the upcoming ASSERT trial data will further support the design of a very effective and efficient ASSURE trial," said Donald J. McCaffrey, President & CEO of Resverlogix.
Resverlogix recently completed a Phase 2 clinical trial called ASSERT to study RVX-208 an oral small molecule therapy for the treatment of atherosclerosis. The ASSERT trial enrolled subjects with stable coronary artery disease. A second planned Phase 2 trial, designated ASSURE, will include subjects with acute coronary syndrome and coronary artery disease of whom all will be examined with intravascular ultrasound (IVUS). Both the ASSERT and ASSURE studies are chaired by Dr. Steven Nissen, MD, Chairman of the Cleveland Clinic Department of Cardiovascular Medicine and the principal investigator is Dr. Stephen Nicholls, Medical Director of Intravascular Ultrasound at the Cleveland Clinic.
Cardiovascular disease is the leading cause of death in the US and other developed nations costing the American health care system an estimated USD$448.5 billion in 2008. According to the American Heart Association's Heart Disease & Stroke Statistics 2010 publication, approximately every 25 seconds an American will have a coronary event and approximately every minute, someone will die from such an event. A key underlying cause of cardiovascular disease is atherosclerosis, a build-up of plaque in the arteries often referred to as 'hardening of the arteries'.
Apolipoprotein A-I (ApoA-I), the main protein component of high-density lipoprotein (HDL), represents the body's natural defense system against atherosclerosis by mediating reverse cholesterol transport, i.e. transport of peripheral cholesterol including that within the atherosclerotic plaques of the vessel wall to the liver for processing and excretion. In multiple human and animal studies over-expression or repeated infusion of ApoA-I inhibit progression and induce regression of atherosclerosis in animals and humans. Developing small molecules that increase ApoA-I would satisfy a large unmet medical need.
About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas(TM) PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp.'s common shares trade on the Toronto Stock Exchange . For further information please visit http://www.resverlogix.com.
This news release may contain certain forward-looking statements as defined under applicable Canadian securities legislation, including our statements with respect to, the current and/or future financings, research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular disease including atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular diseases. These forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous known and unknown risks and uncertainties including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional risk factors discussed in other documents we file from time to time with securities authorities, which are available through SEDAR at http://www.sedar.com. Additionally, risks and uncertainties are discussed in detail in the January 31, 2010 MD&A. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.
For further information: Theresa Kennedy, VP, Corporate Communications, Resverlogix Corp., Phone: +1-403-254-9252 ext. 300, Fax: +1-403-256-8495, Email:Theresa@resverlogix.com
CONTACT: For further information: Theresa Kennedy, VP,
CorporateCommunications,Resverlogix Corp., Phone: +1-403-254-9252
ext. 300, Fax: +1-403-256-8495,Email:Theresa@resverlogix.com